March 7, 2016

**Imbruvica Approved for First-Line CLL**

On March 4, 2016, the U.S. Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib – Pharmacycics and Janssen Biotech) for treatment-naïve patients with chronic lymphocytic leukemia (CLL). Imbruvica, a Bruton's tyrosine kinase (BTK) inhibitor, was first approved in November 2013 for treating relapsed mantle cell lymphoma (MCL). It is also indicated for previously-treated CLL, patients who have CLL with 17p deletion, and Waldenström’s macroglobulinemia (WM). Imbruvica is taken orally once a day as three 140mg capsules (420mg total dose) for CLL and WM or four capsules (560mg total) for MCL. Full prescribing information can be found at: [www.imbruvica.com](http://www.imbruvica.com).